Frédéric Panthier1, Jennifer Pasquier2, Sébastien Bruel3, Vidal Azancot3, Alexandre De La Taille4, Daniel Gasman3. 1. Service de Chirurgie Urologique, CHU Henri-Mondor, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France. fredericpanthier@gmail.com. 2. INSERM U955, Equipe 7, CHU Henri-Mondor, AP-HP, 94000, Créteil, France. 3. Clinique de l'Yvette, 67-71 Route de Corbeil, 91160, Longjumeau, France. 4. Service de Chirurgie Urologique, CHU Henri-Mondor, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France.
Abstract
PURPOSE: To report the functional outcomes, perioperative morbidity and surgical learning curve key points using "en bloc" greenlight enucleation of prostate (EB-GreenLEP) for patients with refractory lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). METHODS: Between December, 2015 and May, 2018, all consecutive patients with refractory LUTS due to BPH in our institution were included and underwent EB-GreenLEP by a single surgeon. Perioperative data, complications and functional outcomes at 1-, 6- and 12-month follow-ups were collected and retrospectively analyzed. RESULTS: One hundred patients were included whose median age was 69 years. The median prostate volume (PV) was 84 mL and median enucleated PV was 45.5 mL. Mean irrigation, catheterization and hospitalization times were 1.3, 1.4 and 1.6 days, respectively. Average follow-up was 9.3 months. A single high-grade Clavien-Dindo complication occurred. No urinary retention was reported. Two conversions to conventional resection of the prostate were noted. Three patients had postoperative urinary incontinence at 6 months, only one at 1 year (1%). At 1, 6 and 12 months, there was a significant improvement in IPSS score, QoL and Qmax. Enucleation and energy efficiency ratios were shorter after the 30th procedure. We demonstrated a linear correlation between enucleation time and PV (r = 0.53, p < 0.0001). CONCLUSION: Our study shows that the mid-term functional results of EB-GreenLEP are comparable to other laser sources for the endoscopic enucleation of the prostate but with a shorter learning curve. We showed that, with (a) low rates of complications and a short hospital stay, EB-GreenLEP can manage medium-size glands (60-90 mL).
PURPOSE: To report the functional outcomes, perioperative morbidity and surgical learning curve key points using "en bloc" greenlight enucleation of prostate (EB-GreenLEP) for patients with refractory lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). METHODS: Between December, 2015 and May, 2018, all consecutive patients with refractory LUTS due to BPH in our institution were included and underwent EB-GreenLEP by a single surgeon. Perioperative data, complications and functional outcomes at 1-, 6- and 12-month follow-ups were collected and retrospectively analyzed. RESULTS: One hundred patients were included whose median age was 69 years. The median prostate volume (PV) was 84 mL and median enucleated PV was 45.5 mL. Mean irrigation, catheterization and hospitalization times were 1.3, 1.4 and 1.6 days, respectively. Average follow-up was 9.3 months. A single high-grade Clavien-Dindo complication occurred. No urinary retention was reported. Two conversions to conventional resection of the prostate were noted. Three patients had postoperative urinary incontinence at 6 months, only one at 1 year (1%). At 1, 6 and 12 months, there was a significant improvement in IPSS score, QoL and Qmax. Enucleation and energy efficiency ratios were shorter after the 30th procedure. We demonstrated a linear correlation between enucleation time and PV (r = 0.53, p < 0.0001). CONCLUSION: Our study shows that the mid-term functional results of EB-GreenLEP are comparable to other laser sources for the endoscopic enucleation of the prostate but with a shorter learning curve. We showed that, with (a) low rates of complications and a short hospital stay, EB-GreenLEP can manage medium-size glands (60-90 mL).
Authors: Luca Cindolo; Lorenzo Ruggera; Paolo Destefanis; Claudio Dadone; Giovanni Ferrari Journal: Int Urol Nephrol Date: 2017-01-02 Impact factor: 2.370
Authors: Mohammad Hout; Aaron Gurayah; Maria Camila Suarez Arbelaez; Ruben Blachman-Braun; Khushi Shah; Thomas R W Herrmann; Hemendra N Shah Journal: World J Urol Date: 2022-10-04 Impact factor: 3.661
Authors: Thomas R W Herrmann; Stavros Gravas; Jean Jmch de la Rosette; Mathias Wolters; Aristotelis G Anastasiadis; Ioannis Giannakis Journal: J Clin Med Date: 2020-05-10 Impact factor: 4.241